Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone


23 Nov 2019


Poster display session


Tumour Site

Pancreatic Adenocarcinoma


Marufjon Salokhiddinov


Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422


M. Salokhiddinov1, S. Matmuratov2, E. Stamou3

Author affiliations

  • 1 Neurooncology, Tashkent Medical Academy, 100109 - Tashkent/UZ
  • 2 General Surgery, Tashkent Medical Academy, 100109 - Tashkent/UZ
  • 3 Medical Physics, University of Aberdeen, AB24 - QP/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 185P


It has been proven that with tumor lesions of the organs of the biliopancreatoduodenal (BPDZ), tumor cells excessively release tumor necrosis factor (TNF-α) in the blood serum and determining their level can assess the activity of the tumor process and the effectiveness of the therapy. Among the causes of mechanical jaundice, the pancreatic head tumor prevailed - 36.1% of patients, in 27.7% of patient's cholestasis was due to a liver gate tumor, in 16.6% - a tumor of the terminal segment of the choledochus, in 13.8% - cancer of the Voter papilla, 5.5% - cancer of the common hepatic duct.


The study involved 32 patients treated at the General Surgery Department in Tashkent Medical Academy with mechanical jaundice (MJ) with malignant etiology after the application of per-cutaneous-transhepatic cholangiostomy (PTCH). The age of patients ranged from 30 to 74 years, averaging 53.7 ± 3.2 years. There were 19 women and 13 men. In order to remove TNF-α from the body, cholesorption was performed.


The initial concentration of TNF-α in serum averaged 467.43 ± 12.36 (in the norm of 0-5.9 pg/ml). The use of cholesorption contributed to a sharp decrease in the concentration of TNF-α in serum and enhancement of its elimination from the bile. On the 3rd day of observation in the serum, there was a decrease in the concentration of TNF-α by 55.7%. The following days, the serum TNF-α concentration tended to increase and on the 6th day, it averaged 242.05 ± 15.6pg / ml. The next day, serum levels showed a gradual decrease in the concentration of TNF-α and on the 10th day of cholesorption averaged 89.46 ± 7.4-65.49 ± 8.95pg / ml, respectively. On the 14th day of cholesorption in comparison with the initial level, the concentration of TNF-α in the serum decreased 5.5 times.


Thus, the use of cholesorption in patients with MJ of tumor genesis contributes to ridding the body of the pro-inflammatory cytokine TNF-α. The determination of TNF-α in the bile increases the objectivity of the method in assessing the course of the main process and the treatment carried out for BPDZ tumors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.